Burning Rock Biotech (NASDAQ:BNR) Ltd., trading on NASDAQ under the ticker BNR, is a China-based precision oncology company specializing in next-generation sequencing (NGS)–driven molecular profiling. The company’s core offerings include tissue- and plasma-based genomic tests designed to detect actionable mutations across a wide range of solid tumors. By providing comprehensive reports on key biomarkers, Burning Rock supports oncologists in selecting targeted therapies and enrolling patients in clinical trials, with a particular focus on lung, colorectal, breast and gastric cancers.
Beyond routine diagnostics, Burning Rock offers custom panels and research-use-only services for pharmaceutical partners and contract research organizations (CROs). Its product portfolio ranges from focused gene panels covering a few dozen genes to broad panels encompassing hundreds of cancer-associated loci. The company also supplies companion diagnostic solutions under collaborative agreements with major biopharmaceutical firms, helping accelerate the development and regulatory approval of targeted therapies.
Founded in 2014 and headquartered in Guangzhou, Burning Rock operates state-of-the-art laboratories in Southern China, including CLIA-certified and CAP-accredited facilities. The company was co-founded by a team of clinical oncologists and molecular biologists and is led by a management group with deep expertise in diagnostics, oncology and regulatory affairs. Burning Rock went public in early 2018, marking a milestone in its growth and expanding its capacity for research and development.
While its primary market remains mainland China, Burning Rock has pursued international expansion through distribution agreements and regulatory filings in Europe and Asia-Pacific regions. The company continues to invest in R&D, exploring emerging technologies such as minimal residual disease monitoring and liquid biopsy assays for early cancer detection. Looking ahead, Burning Rock aims to strengthen its global footprint and advance the adoption of precision medicine in oncology.
